Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07226466
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Brain Metastases From Solid Tumors
  • Brain Tumor
  • Brain Tumor Adult
  • Brain Tumor, Primary

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Blood sample — PROCEDURE
    Blood sample will be collected
  • Brain magnetic resonance imaging (MRI) — PROCEDURE
    Brain MRI will be performed during the course of data collection
  • Brain Health Assessment — PROCEDURE
    Brain Health Assessment will be performed during the course of data collection
  • Quality of Life (QoL) Questionnaire — RADIATION
    QoL questionnaire will be given to participants during the course of data collection

Study Details

This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.

Key Dates

Start date
Jul 1, 2026
Status verified
May 2026
Primary completion
Oct 31, 2028
Completion
Oct 31, 2028

Study Design

Enrollment
40 participants (estimated)

Arms

  • Arm: Adults with Brain Tumor Receiving Radiotherapy
    The study entails longitudinal assessment of plasma biomarkers (Aβ, GFAP, phospho Tau, NfL), determination of APOE genotype, neuropsychiatric testing Brain Health Assessment test (BHA), a clinically validated neurocognitive battery compiling metrics on memory and language), and brain morphometric measurements synchronized with standard of care brain MRIs.

Primary Outcome Measure

Mean change in serum Amyloid-beta peptide (Aβ) [ Time Frame: Up to 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Jean Nakamura, MD
[email protected]
877-827-3222

Find similar trials in San Francisco, CA

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University of California, San Francisco· San Francisco, CA

Related Studies